Regeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis
Source: SeekingAlpha
2026-02-24 10:32:21 ET
More on Regeneron Pharmaceuticals
- Regeneron: Expect Double-Digit Growth In 2026
- Regeneron Pharmaceuticals, Inc. (REGN) Q4 2025 Earnings Call Transcript
- Regeneron Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation
- Regeneron granted FDA priority review for rare bone disorder therapy
- Regeneron outlines 18 new Phase III studies and expects four FDA approvals in 2026 while advancing EYLEA HD and DUPIXENT growth
Read the full article on Seeking Alpha
For further details see:
Regeneron, Sanofi win Dupixent label expansion for allergic fungal rhinosinusitis
Regeneron Pharmaceuticals Inc.
NASDAQ: REGN
REGN Trading
-3.4% G/L:
$754.90 Last:
201,922 Volume:
$764.06 Open:
REGN Latest News
March 12, 2026 04:04:00 am
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making
REGN Stock Data
$80,621,924,056
100,116,656
N/A
714
N/A
Biotechnology & Life Sciences
Healthcare
US
Tarrytown
